Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia

Background Despite the impressive complete remission (CR) induced by CD19 CAR-T cell therapy in B-ALL, the high rate of complete responses is sometimes limited by the emergence of CD19-negative leukemia. Bispecific CAR-modified T cells targeting both CD19 and CD22 may overcome the limitation of CD19...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of hematology and oncology Jg. 13; H. 1; S. 30 - 10
Hauptverfasser:	Dai, Hanren, Wu, Zhiqiang, Jia, Hejin, Tong, Chuan, Guo, Yelei, Ti, Dongdong, Han, Xiao, Liu, Yang, Zhang, Wenying, Wang, Chunmeng, Zhang, Yajing, Chen, Meixia, Yang, Qingming, Wang, Yao, Han, Weidong
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London BioMed Central 03.04.2020 BioMed Central Ltd Springer Nature B.V BMC
Schlagworte:	Acute lymphoblastic leukemia Adolescent Adult Adults Antigens Antigens, CD19 - immunology Autografts B-ALL Bispecific Blast cells Blood Body weight Bone marrow Cancer Research CAR CD19 CD19 antigen CD22 CD22 antigen Cell therapy Cerebrospinal fluid Chemotherapy Clinical trials Cytokines Cytolytic activity FDA approval Female Flow cytometry Hematology Humans Immunotherapy Immunotherapy, Adoptive - adverse effects Immunotherapy, Adoptive - methods Leukemia Lymphatic leukemia Lymphocytes Lymphocytes T Male Medicine Medicine & Public Health Neoplasm Recurrence, Local - immunology Neoplasm Recurrence, Local - therapy Neurotoxicity Oncology Patients Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - immunology Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - therapy Rapid Communication Remission Sialic Acid Binding Ig-like Lectin 2 - immunology T cells Tisagenlecleucel Treatment Outcome Young Adult B-ALL CAR Bispecific CD19 Immunotherapy Tumor antigen escape CD22
ISSN:	1756-8722, 1756-8722
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!